PFE
Pfizer Inc Health Care Pharmaceutical Preparations S&P 500Russell 3000
$30.52Close
$293.6BMarket cap
$22.70 – $30.5252-week range
Nov 3, 2026Next report · before the open
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 80 · stronger than 80% of stocks over 12 months
- Near its high at its 52-week high
Cautions
- Earnings shrinking EPS −109% year on year
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 1.6%
price change
1mo
up 7.0%
price change
12-month return
up 34%
market up 11% ·
its own up 24%
F-score
6 / 9
Mixed
Altman Z
2.72
Moderate risk
P/E
37.8×
price / earnings
PEG
—
P/E / EPS growth
P/B
3.4×
price / book
Earnings yield
up 2.9%
EBIT / enterprise value
Cheaper than
47%
of the market · around average
Revenue growth
down 2%
year on year
EPS growth
down 109%
latest quarter · -99 pts
Sales growth
up 3%
latest quarter · -3 pts
ROE
up 9%
return on equity
Free cash margin
up 15%
$9.1B FCF
D/E
0.71
long-term debt / equity
Net debt / EBITDA
3.6×
Interest cover
3.8×EBIT / interest
Piotroski tests
- took on more long-term debt
- short-term liquidity weakened
- issued more shares
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- gross margin widened
- assets working harder
Repair signals
- Gross margin 71.9% → 74.3%
Trade setup
ATR%
1.9%
$0.57 a day · 2×ATR $29.37
RS
80 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.4×
vs 50-day average
Up/down volume
1.33
50 sessions
Implied move
4.4%
by Nov 6, 2026 · report Nov 3, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Revenue shrinking Revenue fell 1.6% over the year, from $63.6B to $62.6B.
Last reported
Aug 4, 2026
Results reaction
Aug 4, 2026+2% vs market2 sessions after results
Options
$11.2M27.9% IV · activity
Financials
- Gross 74%
- Net 12%
- Free cash 15%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $41.7B | $73.6B | $91.8B | $50.9B | $63.6B | $62.6B |
| Gross margin | 80% | 58% | 63% | 51% | 72% | 74% |
| Net income | $9.2B | $22.0B | $31.4B | $2.1B | $8.0B | $7.8B |
| Net margin | 22% | 30% | 34% | 4% | 13% | 12% |
| Earnings per share | $1.63 | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 |
| Free cash flow | $12.2B | $29.9B | $26.0B | $4.8B | $9.8B | $9.1B |
| Free cash margin | 29% | 41% | 28% | 9% | 15% | 15% |
| Cash | $1.8B | $1.9B | $416.0M | $2.9B | $1.0B | $1.1B |
| Long-term debt | $37.1B | $36.2B | $32.9B | $61.5B | $57.4B | $61.6B |
| Shareholders' equity | $63.2B | $77.2B | $95.7B | $89.0B | $88.2B | $86.5B |
| Shares outstanding | 9.41bn | 9.47bn | 9.52bn | 9.56bn | 9.59bn | 9.62bn |
Next report
Nov 3, 2026 · before the open
Expected move The move, either way, the option market prices in through the next scheduled report: the at-the-money straddle for the first expiry that contains it, over the price. It includes the days around the report, so it slightly overstates the report alone. Methodology
±4.4%
$29 – $32 by Nov 6, 2026
Usual move The median, over the company's last four reports, of how far the stock moved either way from the close before the filing to the close of the session after it. Methodology
±0.7%
last 4: +3.1% · +0.9% · +0.5% · -0.2%
Expected against usual The move the options price through this report over the move the last four reports delivered. Above 1 the event is priced bigger than the company's own record; below 1, smaller. A price, not a forecast: it says what protection through the report costs, not which way the stock will go. Methodology
Bigger than usual
6.7× the usual move
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $29 – $32 ±6.2% by Nov 27, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 27.9% priced · 21.0% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs more
Positioning
- Premium traded
- $11.2M calls $8.0M · puts $3.2M · latest session
- 0.40× +0.12 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls -34.77k · puts -27.61k past week
For options traders: ATM IV 27.9% (+2.1% 1w) · 1m ÷ 3m IV 1.12 · 25Δ skew 1.2 pts · Net GEX $48.6M
Most traded contracts 2
| Contract | Next day: opened, closed or mixed A large option trade on its own is ambiguous: it may have opened a position, closed one, or been one leg of a spread. Open interest is published overnight, so the next morning settles it. Opened: open interest rose by a good share of the volume traded, so positions were added. Closed: it fell, so positions were taken off. Mixed: it barely moved, as when one side opens while the other closes. A dash: the next morning's count is not in yet. None of the three says whether the contracts were bought or sold. Methodology | Volume against open interest The day's contracts traded, divided by the positions already standing. Above 1 the day's trading exceeded every position in existence, which cannot happen without something new — though only tomorrow's open interest proves it opened rather than closed. Methodology | Bid-ask spread The gap between the bid and the ask as a share of the midpoint: what a round trip costs before the position has moved at all. Methodology | Priced vs rest of chain The contract's implied volatility less the at-the-money reading for the same company, in points: how this strike is priced against the rest of the chain. Methodology | Move to break even How far the stock must move by expiry for a buyer at the midpoint to get the premium back: strike plus premium for a call, strike less premium for a put. Methodology | Premium |
|---|---|---|---|---|---|---|
| Dec 18, 2026 · $33 call +8% from price | — | 0.07 | 3.1% | -1.0% | +9.4% | $38,058 |
| Jan 15, 2027 · $30 call -1% from price | — | 0.02 | 2.5% | -2.7% | +3.7% | $221,042 |
Liquid contracts, 3 weeks to 4 months out, soonest expiry first.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 28, 2026 | 37d |
| May 5, 2026 | Quarterly ↗ | Mar 29, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 4, 2025 | Quarterly ↗ | Sep 28, 2025 | 37d |
| Aug 5, 2025 | Quarterly ↗ | Jun 29, 2025 | 37d |
| May 5, 2025 | Quarterly ↗ | Mar 30, 2025 | 36d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 4, 2024 | Quarterly ↗ | Sep 29, 2024 | 36d |
| Aug 5, 2024 | Quarterly ↗ | Jun 30, 2024 | 36d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
| Nov 8, 2023 | Quarterly ↗ | Oct 1, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 4, 2026 | Results ↗ |
| Jun 18, 2026 | Regulation FD ↗ |
| Jun 18, 2026 | Director or officer change ↗ |
| May 5, 2026 | Results ↗ |
| Apr 27, 2026 | Shareholder vote ↗ |
| Feb 3, 2026 | Results ↗ |
| Dec 16, 2025 | Regulation FD ↗ |
| Nov 21, 2025 | Other events ↗ |
| Nov 13, 2025 | Other events ↗ |
| Nov 4, 2025 | Results ↗ |
| Aug 5, 2025 | Results ↗ |
| May 19, 2025 | Other events ↗ |